Can a Tiny Insider Buy at Conagra Signal the Next Big Bull?
Conagra might not be hot sauce, but it’s finally warming up. A small insider buy, strong institutional backing, and a fat dividend yield could turn this frozen-aisle veteran into a comeback story. Just keep an eye on inflation and margins — both can melt fast.
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Directors' Thirst for Shares of Global Water Resources Seems Unquenchable. Should You Binge on Them?
Insiders are gulping up shares of Global Water Resources, betting big on Arizona’s thirst for growth. But while the company’s outlook is steady, its valuation might leave you parched. Sip wisely. 💧📈
CarMax (KMX): Where Insiders Keep Buying — And Cars Keep Driving Off (Mostly the Lot)
Insiders and institutions are revving up for CarMax’s comeback — even as used car sales slow and margins tighten. With shares 70% below their peak and a major digital overhaul underway, this could be the turnaround ride of the year. 🚘📉 Or just another trip to the mechanic.
W&T Offshore (WTI): CEO Buys Shares, But the Tide May Still Be Out
W&T Offshore (WTI): Deep Value or Deep Trouble?
Houston’s oil-and-gas veteran has been drilling for 40 years — and shareholders are still waiting to strike gold. With the CEO buying more shares while shorts circle overhead, the battle for the Gulf of America’s future is heating up. Production’s up, cash flow’s steady, and the dividend still drips — but with a stock 97% below its all-time high, is this a comeback story or a cautionary tale?
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?
CEO Bought Shares Higher A Year Ago. Will RH Restore Investor Confidence?
RH stock has crashed, but its CEO is still buying, funds are backing, and Paris is shining. With shorts circling and debt looming, is RH a comeback story—or just a fancy couch with shaky legs?
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?